Taking aim at Astellas and Medivation, J&J moves prostate cancer drug into late-stage testing
This article was originally published in Scrip
Johnson & Johnson moved a recently acquired prostate cancer drug into late-stage testing as it tries to keep its market lead over rivals Astellas Pharma and Medivation.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.